CION Ameerpet
HE4 exists because CA-125 has a specific weakness: it is raised by endometriosis, fibroids and other benign conditions that are extremely common in younger women. HE4 is much less affected by those, which is precisely what makes the pair useful together.
CA-125's weakness is well known and is covered in detail on our CA-125 page: it is produced not only by ovarian tissue but by the peritoneum, pleura and pericardium, so almost anything that irritates those surfaces raises it. Endometriosis, fibroids, pelvic infection, liver disease and even a normal period all push it up, entirely benignly.
That matters most in premenopausal women, where exactly those conditions are common. A raised CA-125 in a 34-year-old with an ovarian cyst frequently reflects endometriosis rather than anything sinister — but the raised number still generates alarm and sometimes unnecessary tests.
HE4 behaves differently. It is elevated in many epithelial ovarian cancers but is substantially less affected by benign gynaecological conditions. So where CA-125 alone leaves a genuinely ambiguous picture, adding HE4 can help separate a benign explanation from one that needs specialist assessment. It is a companion test rather than a replacement — neither is used alone, and both are read alongside the scan.
Endometriosis, fibroids, infection and menstruation all raise it, which is worst in premenopausal women.
Elevated in many epithelial ovarian cancers but far less affected by common benign gynaecological conditions.
Neither marker is diagnostic by itself, and both are interpreted alongside the ultrasound.
ROMA is a triage tool, not a diagnosis, and confusing the two causes real distress. It combines CA-125, HE4 and menopausal status into a score that places a woman with a known adnexal mass into a low-risk or high-risk group — and its purpose is to determine which service should manage her. A high-risk score means referral to a specialist gynaecologic-oncology team, because outcomes are better where those masses are handled by specialists. It is not a percentage chance that she has cancer, and a substantial proportion of women placed in the high-risk group turn out to have benign disease. Source: published ROMA validation studies; standard triage practice.
They have different strengths and different blind spots, which is precisely why they are used together.
| CA-125 | HE4 | |
|---|---|---|
| Raised by endometriosis | Frequently and substantially. | Much less so. |
| Raised by fibroids | Commonly. | Much less so. |
| Raised during menstruation | Yes, often noticeably. | Little affected. |
| Raised in pregnancy | Yes, physiologically. Test is uninterpretable. | Also affected; not used in pregnancy. |
| Raised by liver or kidney disease | Liver disease and ascites raise it. | Kidney impairment raises it — a distinct pitfall. |
| Raised by smoking and age | Not particularly. | Yes, both raise HE4 independently. |
| Useful in mucinous ovarian cancer | Often low even with disease present. | Also often low. Neither marker performs well here. |
| Used for monitoring after diagnosis | Yes — the main established use. | Less established for this purpose. |
*Note the reversal: kidney impairment, age and smoking raise HE4 while barely affecting CA-125. Each marker has its own confounders, which is why the scan still leads.
The value is narrower and more specific than a general "better ovarian cancer test", which is how they are sometimes presented.
A woman in her thirties with an ovarian cyst and a moderately raised CA-125 is the classic difficult case. The marker may reflect endometriosis, a fibroid uterus or simply the timing of the test in her cycle — or it may reflect something else. The scan is the primary evidence, but where it too is indeterminate, the picture is genuinely unclear.
Here HE4 can add real information, because it is far less affected by those benign confounders. A normal HE4 alongside a raised CA-125 in this situation is reassuring in a way a repeat CA-125 would not be.
This is the established purpose of ROMA. Ovarian cancer outcomes are better when staging and debulking surgery are performed by specialist gynaecologic-oncology surgeons, so getting the right women to those services matters considerably.
A scoring system that reliably sorts masses into low and high risk groups achieves that, without requiring every woman with a cyst to attend a cancer centre. That is a genuine benefit even though the score tells no individual woman whether she has cancer.
Neither HE4 nor ROMA is a screening test, and neither should be ordered in a woman with no ovarian abnormality. ROMA is specifically designed and validated for women who already have a known adnexal mass — applying it outside that context produces results that cannot be interpreted meaningfully.
Ordering these markers as a general check has the same problem as ordering CA-125 that way: it generates raised results in well women that lead to imaging, anxiety and occasionally unnecessary surgery, with no demonstrated benefit.
HE4 is not free of false positives; it simply has different ones. Kidney impairment raises HE4, sometimes substantially, and this catches people out because it is not intuitive. Age and smoking also raise it independently of any disease.
So a raised HE4 in a woman with reduced kidney function needs interpreting with that in mind rather than taken at face value. If your kidney function is impaired and your HE4 was raised, it is worth asking specifically whether that was factored in.
Mucinous ovarian cancers frequently produce little CA-125, and they often produce little HE4 either. In these tumours, both markers can be entirely normal while disease is present, and a reassuring score would be misleading.
This is one of the clearest reasons the imaging leads rather than the bloods. A concerning ultrasound appearance with normal markers still warrants full assessment, and a low ROMA score should never be used to dismiss a worrying scan.
HE4 is not universally available and not every service uses ROMA — many use the Risk of Malignancy Index instead, which combines an ultrasound score, menopausal status and CA-125. Both are triage tools serving the same purpose, and neither is clearly superior in all situations.
If your assessment used RMI rather than ROMA, that is entirely standard rather than a lesser work-up. See the Risk of Malignancy Index.
These are the questions that make a ROMA result interpretable rather than alarming.
Low or high. Ask specifically what it changes — usually which service manages you, not what you have.
The imaging leads. A score alongside a reassuring scan reads very differently from one alongside a solid mass.
ROMA uses different thresholds before and after menopause. A misclassification changes the result.
Kidney impairment raises HE4 independently. If yours is reduced, ask whether that was accounted for.
Both markers can be normal in mucinous cancers. A low score does not override a concerning scan.
A score should lead to an action — referral, MRI, or planned follow-up. Ask what yours triggers.
A high-risk ROMA score means you are being sent to the right team. A substantial proportion of women in that group turn out to have benign disease.
ROMA places you in a risk group so you reach the right team. It is not a probability that you have cancer, and it is frequently handed over as though it were.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them - together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
No referral needed and no cost for the first consultation. Bring both marker values and your scan report — the score only means anything alongside the imaging.
Scores are unusually easy to misread because they arrive looking authoritative — a single number with a category attached. Being placed in a high-risk group sounds like being told something about your body, when what it actually determines is which clinic manages you.
Your first consultation at CION is free and runs to about 45 minutes. Bring both marker values and the scan report, because the score means very little without the imaging alongside it. Much of the useful work is straightforward: explaining which group you are in, what it triggers, and — often the more relevant point — what the ultrasound appearance suggests independently of any score.
We will also say when these tests should not have been ordered. HE4 and ROMA are designed for women with a known adnexal mass; used as a general check they produce uninterpretable results and unnecessary alarm. Where the combined picture does warrant it, care moves to a gynaecologic-oncology pathway with a tumour-board discussion. Chemotherapy and maintenance treatment are delivered in-house across 35+ centres, while surgery is coordinated with specialist partner centres and may be billed there.
Free and unhurried. Long enough to explain what a score does and does not tell you.
The score is close to meaningless without the imaging it was designed to accompany.
ROMA in a woman with no ovarian abnormality produces uninterpretable results. We will say so.
Assessment and any subsequent care near where you live across Telangana and Andhra Pradesh.
It is worth stepping back from the markers entirely for a moment. For characterising an ovarian mass, ultrasound in trained hands remains the most informative single test — more so than CA-125, more so than HE4, and more so than either score built from them.
Standardised systems based purely on ultrasound features classify the large majority of adnexal masses confidently as benign or concerning, leaving only a minority genuinely indeterminate. The markers earn their place mainly in that minority, and in triage — deciding which service should manage a woman rather than what she has.
This matters practically. If your scan showed a simple cyst with clear fluid, thin walls, one compartment and no blood flow, that is a strongly reassuring finding whatever your markers say. And conversely, a solid mass with internal blood flow warrants full assessment even if every blood test comes back normal. The bloods modify the picture; the imaging draws it. See reading a scan report.
In trained hands it characterises most masses confidently — more informative than any marker.
They earn their place in the genuinely indeterminate minority, and in triage.
A simple cyst with no solid areas or flow is a strong finding whatever the markers show.
A solid mass with internal flow warrants assessment even with entirely normal blood tests.
HE4 is a second tumour marker used alongside CA-125 rather than instead of it. Its value lies in a specific difference: CA-125 is raised by endometriosis, fibroids, pelvic infection, liver disease and even menstruation, which are all common in premenopausal women and produce a great many falsely alarming results. HE4 is elevated in many epithelial ovarian cancers but is substantially less affected by those benign gynaecological conditions. So where a raised CA-125 leaves a genuinely ambiguous picture, adding HE4 can help separate a benign explanation from one needing specialist assessment.
It means you have been placed in a high-risk group and should be managed by a specialist gynaecologic-oncology service rather than locally. That is what the score is for — it is a triage tool, designed to get women with adnexal masses to the right team, because outcomes are better where such masses are handled by specialists. It is important to understand what it is not: it is not a percentage probability that you have cancer, and a substantial proportion of women placed in the high-risk group turn out to have entirely benign disease.
Only if you have a known ovarian mass — that is the context ROMA was designed and validated for. Ordered in a woman with no ovarian abnormality, as a general check, it produces results that cannot be interpreted meaningfully and carries the same problem as ordering CA-125 that way: raised results in well women leading to imaging, anxiety and occasionally unnecessary surgery, with no demonstrated benefit. It is also worth knowing that many services use the Risk of Malignancy Index instead of ROMA, which is entirely standard rather than a lesser work-up.
Yes — it simply has different confounders from CA-125 rather than none. The most notable is kidney impairment, which raises HE4 sometimes substantially and catches people out because it is not intuitive. Age and smoking also raise it independently of any disease. So a raised HE4 in a woman with reduced kidney function needs interpreting with that in mind rather than taken at face value. If your kidney function is impaired and your HE4 came back raised, it is worth asking specifically whether that was factored into the interpretation.
The imaging leads, and a normal marker should not be used to dismiss a concerning scan. This matters particularly for mucinous ovarian cancers, which frequently produce little CA-125 and often little HE4 either — so both markers can be entirely normal while disease is present, and a reassuring score would be actively misleading. A solid mass with internal blood flow on Doppler warrants full assessment regardless of what the blood tests show. Ultrasound in trained hands remains the most informative single test for characterising an ovarian mass.
Neither is clearly superior in all situations, and both serve the same purpose. ROMA combines CA-125, HE4 and menopausal status. RMI combines an ultrasound feature score, menopausal status and CA-125 — so it incorporates the imaging directly, which is an advantage, while ROMA incorporates a second marker less affected by benign disease. Which is used depends largely on local practice and whether HE4 testing is available. If your assessment used RMI rather than ROMA, that is entirely standard rather than a lesser work-up.
The first consultation is free and runs to about 45 minutes — bring both marker values and your scan report, since the score means very little without the imaging alongside it. Much of the useful work is explaining which risk group you are in, what it actually triggers, and what the ultrasound suggests independently of any score. Where the combined picture warrants it, care moves to a gynaecologic-oncology pathway with a tumour-board discussion. Chemotherapy and maintenance treatment are delivered in-house across more than 35 centres; surgery is coordinated with specialist partner centres and may be billed there.